Guggenheim Upgrades Price Targets for Amylyx, Salesforce, and Guidewire

Guggenheim Securities has raised its price targets for Amylyx Pharmaceuticals, Salesforce, and Guidewire Software, highlighting positive developments in clinical trials, AI integration, and recurring revenue outlooks. The adjustments signal improved analyst sentiment across healthcare, enterprise software, and insurance tech sectors.